An NCI-designated Comprehensive Cancer Center

Ryotaro Nakamura, M.D.

Clinical Expertise
Research Focus
  • Hematopoietic Stem Cell (Bone Marrow) Transplantation
  • Graft Versus Host Disease
Professor, Department of Hematology & Hematopoietic Cell Transplantation; Director, Center for Stem Cell Transplantation
Other Languages Spoken
  • Japanese

Clinical Teams

Research Teams

  • Hematology & Hematopoietic Cell Transplantation
Since joining City of Hope in 2002, Ryotaro Nakamura, M.D., has been at the forefront of leading-edge research in stem cell transplantation and development of cancer vaccines. Among his promising projects: A study indicating that bone marrow transplants may be effective in treating systemic mastocytosis, a rare blood disease with no known cure, and the use of vaccines to replace antivirals which can often spawn deadly infections.
Dr. Nakamura trained in Japan and served a fellowship in hematology and oncology at the National Institutes of Health in Bethesda, Maryland, before arriving at City of Hope’s Hematologic Malignancies and Stem Cell Transplantation Institute, which includes the Judy and Bernard Briskin Center for Multiple Myeloma Research, Toni Stephenson Lymphoma Center and Gehr Family Center for Leukemia Research.


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

In The News
An Expert's Voice
Ryotaro Nakamura 256x256

COVID-19 and BMT: Delivering care in a crisis

Measles Virus | City of Hope

City of Hope-developed CMV vaccine reduces post-transplant complications

City of Hope News

City of Hope’s Triplex vaccine reduces rate of CMV complications in transplant recipients by 50 percent and spurs immunity against the virus